🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

1/ #ESMO4Carers: What factors are critical to #ProfessionalWellbeing in the #HealthcareWorkforce? The ESMO #Resilience Task Force has just published actionable recommendations to mitigate the risk of #burnout in the oncology community. 📌 ow.ly/Xw8C50TjSBl

In this JAMA Oncology Viewpoint, William A Hall, MD & I discuss a big challenge for radiation trials: patient accrual. We explain several reasons why RT trials have difficulty enrolling & propose potential solutions. Please take a read & share thoughts! jamanetwork.com/journals/jamao…

.CARO-ACRO #CAROASM2024 Theme Symposium Resilience of Self and System… Name the RIGHT_Lung lol #TG263 American Association of Physicists in Medicine AAPM TG263

Lunch Symposium CARO-ACRO #CAROASM2024 with Merck : Navigating the Era of Immunotherapy as a #Radiation Oncologist

SIMULTANEOUS PUBLICATION ALERT!🚨 As I mentioned in my talk, a comprehensive review answering most frequently asked questions on surrogate endpoints in oncology has been simultaneously published in eClinicalMedicine – The Lancet Discovery Science today with our ESMO - Eur. Oncology MCBS session. OPEN ACCESS.

It was an honor presenting primary results of DB-12 at #ESMO2024 In the 🧠 mets cohort: -12 mo PFS 61.6% -median PFS 17.3 mo -CNS ORR 71% (82% in pts w/untreated active brain mets) -12 mo OS > 90% Looking forward to seeing readouts of trials testing other ADCs for brain mets!

Excited to share that our BMJ paper on hypofractionated radiation therapy for breast cancer is published! 🎉 Big thanks to colleagues, and international experts for all the support. Grateful for this amazing collaboration! bmj.com/content/386/bm…

Among patients with triple-negative breast cancer, 5-year survival was 86.6% with neoadjuvant pembrolizumab with chemotherapy followed by adjuvant pembrolizumab and 81.7% with neoadjuvant chemotherapy alone. Full KEYNOTE-522 trial results: nej.md/3XzBOIS #ESMO24

Peter Schmid presents the OS data from KN522 #ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% ⬆️OS with pembro pre/post op for TNBC. Pts with PCR had 95% survival +/-pembro but 6% ⬆️OS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers! OncoAlert

Hypofractionated #radiation therapy in early #breastcancer - 5-year results from UNICANCER HypoG-01 phase 3 trial #ESMO24 Non inferior as compared to 2Gy-fractionation: moderate hypofractionation preferred standard of care for nodal irradiation OncoAlert #OncoAlert #radonc

Great discussant prof Charlotte Coles at Presidential Symposium II: Practice-changing trials. OncoAlert #OncoAlertAF #ESMO24 👉🏻 Data from >5.800 participants in RCTs testing 3-week vs 5-week nodal RT •No statistically significant differences in late normal tissue effects

Original Article: Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer (DESTINY-Breast06) nej.md/3TovTE9 #ESMO24 | ESMO - Eur. Oncology

Randomized phase 2 trial evaluating SBRT to the Primary Breast Cancer +/- Durvalumab +/- Oleclumab combined with Neoadjuvant Chemotherapy for Early-Stage High Risk ER+/HER2- 👉 high rates of pCR especially in PD-L1 neg pts

#ESMO2024 Mgmt of Oligoprogressive #bcsm

#ESMO2024. OPD in #bcsm specifically LMD. ?role for CSF ctDNA. ?CSI with protons or VMAT sufficient. The future can only get better…

#ESMO2024 Nancy Lin, MD masterclass on brain mets #bcsm

Rad Oncs at #ESMO24 Robbe Van den Begin on oligoprogressive bone metastases in #bcsm

#ESMO24 ESMO - Eur. Oncology Congress Highlights on Early Stage #bcsm NA IO

#ESMO24 ESMO - Eur. Oncology Congress Highlights on Early Stage #bcsm Neoadj IO, Hypofrac RNI, Adj cdk4/6i, Adj AI + OFS

If you want to stay up to date with major highlights from #ESMO24 but want to avoid the hype, you have to watch this. You’ll learn more than a mere regurgitation of data without context and “oh wow this is new standard of care and game changer and congratulations to everyone”